Elisa Tsao

1.3k citations

21 papers · 970 indexed · h-index 11

Co-authors: AW Sandrock Jeffrey A. Cohen Mariska Kooijmans Gary Cutter Jill S. Fischer Richard A. Rudick John N. Whitaker Fedor Heidenreich
Topics: Hemophilia Treatment and Research (14 papers)Platelet Disorders and Treatments (6 papers)Blood Coagulation and Thrombosis Mechanisms (4 papers)
Cited by: Rheumatology Pathology and Forensic Medicine Hematology
Journals: Blood Neurology Pediatric Research
Partner nations: United States United Kingdom Canada

In The Last Decade

Elisa Tsao

21 papers receiving 933 citations

Peers

Countries citing papers authored by Elisa Tsao

Since Specialization

Citations

This map shows the geographic impact of Elisa Tsao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Tsao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Tsao more than expected).

Fields of papers citing papers by Elisa Tsao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Tsao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Tsao. The network helps show where Elisa Tsao may publish in the future.

Co-authorship network of co-authors of Elisa Tsao

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Tsao. A scholar is included among the top collaborators of Elisa Tsao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Tsao. Elisa Tsao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan 2020 ·International Journal of Hematology ·Toyomi Kamesaki,Junichi Nishimura,Hideho Wada,Eric Yu,Elisa Tsao,(unknown),Yuzuru Kanakura	13
2	Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years 2020 ·Haemophilia ·Amy D. Shapiro,(unknown),Michael Wang,Miguel A. Escobar,Elisa Tsao,(unknown),Jing Feng,Nisha Jain,Doris Quon	10
3	Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow‐up retrospective analysis 2020 ·Haemophilia ·Manuel Carção,Amy D. Shapiro,(unknown),Steven W. Pipe,Sanjay Ahuja,(unknown),Janice M. Staber,Mark Belletrutti,Haowei Sun,(unknown),Michael Wang,Victoria Price,MacGregor Steele,Elisa Tsao,Jing Feng,(unknown),Jennifer Dumont,Nisha Jain	10
4	Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review 2020 ·Haemophilia ·(unknown),Robert F. Sidonio,(unknown),Elisa Tsao,(unknown),(unknown),Roshni Kulkarni	22
5	PF431 CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND THROMBOEMBOLIC RISK OF PATIENTS WITH COLD AGGLUTININ DISEASE (CAD) IN JAPAN 2019 ·HemaSphere ·Toyomi Kamesaki,J Nishimura,Hideho Wada,(unknown),Elisa Tsao,(unknown),Yuzuru Kanakura	2
6	Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors—A retrospective analysis 2018 ·Haemophilia ·Manuel Carção,Amy D. Shapiro,Janice M. Staber,(unknown),Colleen Druzgal,Kenneth Lieuw,Mark Belletrutti,Courtney D. Thornburg,Sanjay Ahuja,Jaime Morales‐Arias,Jennifer Dumont,Gavin Miyasato,Elisa Tsao,Nisha Jain,Steven W. Pipe	32
7	Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure 2018 ·Blood ·Manuel Carção,Amy D. Shapiro,(unknown),Steven W. Pipe,Sanjay Ahuja,Kenneth Lieuw,Janice M. Staber,Haowei Sun,(unknown),Michael Wang,MacGregor Steele,Elisa Tsao,Jing Feng,(unknown),Jennifer Dumont,Nisha Jain	1
8	Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden 2018 ·Blood ·Amy D. Shapiro,(unknown),(unknown),Elisa Tsao,(unknown),(unknown),Doris Quon	4
9	Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein 2017 ·Haemophilia ·Johannes Oldenburg,Roshni Kulkarni,Alok Srivastava,Johnny Mahlangu,Victor S. Blanchette,Elisa Tsao,Bent Winding,Jennifer Dumont,Nisha Jain	38
10	Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A 2017 ·Haemophilia ·Amy D. Shapiro,Johnny Mahlangu,David J. Perry,John Pasi,Doris Quon,Pratima Chowdary,Elisa Tsao,(unknown),Alison Innes,Glenn F. Pierce,Geoffrey Allen	10
11	Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Severe Hemophilia a 2016 ·Blood ·Guy Young,(unknown),John Pasi,Beatrice Nolan,Stefan Lethagen,Lynda M. Cristiano,Elisa Tsao,Bent Winding,Johnny Mahlangu	1
12	Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies 2015 ·Blood ·Roshni Kulkarni,Amy D. Shapiro,Jerzy Windyga,Margaret V. Ragni,John Pasi,Margareth C. Ozelo,Elisa Tsao,Baisong Mei	3
13	Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies 2015 ·Blood ·Doris Quon,Robert Klamroth,Roshni Kulkarni,Amy D. Shapiro,Ross Baker,Giancarlo Castaman,Bryce A. Kerlin,Elisa Tsao,Geoffrey Allen	2
14	Analysis of Target Joint Bleeding with Prophylactic Use of Recombinant Factor IX Fc Fusion Protein in Patients with Severe Hemophilia B 2015 ·Blood ·Amy D. Shapiro,David J. Perry,Ross Baker,Elisa Tsao,Baisong Mei	1
15	Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE 2015 ·Blood ·John Pasi,David J. Perry,Johnny Mahlangu,Barbara A. Konkle,Savita Rangarajan,Simon Brown,Hideji Hanabusa,Shannon Jackson,Ingrid Pabinger,Lynda M. Cristiano,Yingwen Dong,Elisa Tsao,Glenn F. Pierce,Geoffrey Allen	5
16	Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa 2012 ·Molecular Genetics and Metabolism ·Ans T. van der Ploeg,Richard J. Barohn,Lisa Carlson,Joel Charrow,Paula R. Clemens,Robert J. Hopkin,Priya S. Kishnani,Pascal Laforêt,Claire Morgan,Sharon Nations,Alan Pestronk,Horacio Plotkin,Barry E. Rosenbloom,Katherine B. Sims,Elisa Tsao	85
17	Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease 2009 ·Pediatric Research ·Priya S. Kishnani,Deya Corzo,Nancy D. Leslie,Daniel Gruskin,Ans van der Ploeg,John Clancy,Rossella Parini,Gilles Morin,Michael Beck,Mislen Bauer,(unknown),(unknown),(unknown),Claire Morgan,Tara O’Meara,Susan Richards,Elisa Tsao,Hanna Mandel	232
18	Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study 2006 ·Multiple Sclerosis Journal ·Deborah Miller,Jeffrey A. Cohen,Mariska Kooijmans,Elisa Tsao,Gary Cutter,Monika Baier,(unknown)	22
19	Benefit of interferon β-1a on MSFC progression in secondary progressive MS 2002 ·Neurology ·Jeffrey A. Cohen,Gary Cutter,Jill S. Fischer,Andrew Goodman,Fedor Heidenreich,Mariska Kooijmans,AW Sandrock,Richard A. Rudick,Jack H. Simon,Nancy A. Simonian,Elisa Tsao,John N. Whitaker	307
20	A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS 2002 ·Neurology ·Michel Clanet,Ernst‐Wilhelm Radue,Ludwig Kappos,HP Hartung,Reinhard Hohlfeld,Magnhild Sandberg‐Wollheim,M. F. Kooijmans-Coutinho,Elisa Tsao,AW Sandrock,(unknown)	166

About Elisa Tsao

Elisa Tsao is a scholar working on Hematology, Genetics and Rheumatology, having authored 21 papers that have together received 970 indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (14 papers), Platelet Disorders and Treatments (6 papers) and Blood Coagulation and Thrombosis Mechanisms (4 papers). The work is most often cited by research in Rheumatology (438 citations), Pathology and Forensic Medicine (474 citations) and Hematology (190 citations). Elisa Tsao has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include AW Sandrock, Jeffrey A. Cohen, Mariska Kooijmans, Gary Cutter, Jill S. Fischer, Richard A. Rudick, John N. Whitaker, Fedor Heidenreich, Nancy A. Simonian and Andrew Goodman. Their work appears in journals such as Blood, Neurology and Pediatric Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact